{"entity":{"id":"bemarituzumab","kind":"drug","name":"Bemarituzumab","aka":[],"tldr":"Bemarituzumab is an antibody against FGFR2b, a growth receptor overproduced in about a third of stomach cancers. It improved survival early in its phase 3 trial, but the gain faded with longer follow-up.","summary":"Afucosylated IgG1 blocking FGFR2b ligand binding and enhancing ADCC. FORTITUDE-101: interim OS 17.9 vs 12.5 months (HR 0.61) in FGFR2b ≥10% 2+/3+ tumours, attenuated at updated analysis (ESMO 2025). Corneal adverse events are frequent. FORTITUDE-102 adds nivolumab. The regulatory path was still uncertain in September 2026.","status":"phase-3","asOf":"2026-09-07","links":[{"label":"Amgen topline announcement","url":"https://www.amgen.com/newsroom/press-releases/2025/06/amgen-announces-positive-topline-phase-3-results-for-bemarituzumab-in-fibroblast-growth-factor-receptor-2b-fgfr2b-positive-firstline-gastric-cancer"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":["monoclonal-antibody"],"targets":["fgfr2"],"drugs":[],"companies":["amgen"],"institutions":[],"pathways":["ras-mapk"],"terms":[],"trials":["fortitude-101"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"FPA144","modality":"Monoclonal antibody (anti-FGFR2b)","mechanism":"Blocks FGF ligand binding to FGFR2b and recruits NK-mediated ADCC.","approvals":[],"mechanismSteps":["Bemarituzumab binds the FGFR2b receptor on tumour cells","Growth-factor ligands can no longer activate it","Downstream RAS-MAPK signalling drops","The afucosylated antibody tail recruits NK cells to kill the coated cells"],"toxicity":[{"event":"Corneal adverse events (keratitis, dry eye)","note":"Frequent; dose-limiting"},{"event":"Stomatitis"}],"access":[],"regulatoryEvents":[]},"route":"/drugs/bemarituzumab/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}],"pathway":[{"id":"fgfr-signalling","kind":"pathway","name":"FGF / FGFR signalling","route":"/pathways/fgfr-signalling/"},{"id":"gastric-cancer-signalling","kind":"pathway","name":"Gastric cancer (KEGG map)","route":"/pathways/gastric-cancer-signalling/"},{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/"}],"trial":[{"id":"fortitude-101","kind":"trial","name":"FORTITUDE-101","route":"/trials/fortitude-101/"}]}}